enGene Therapeutics Inc (ENGN) Stock Analysis

AI analysis of enGene Therapeutics Inc (ENGN)

Sell

enGene Holdings Inc is not a good buy right now due to significant financial losses and negative analyst sentiment. The current price is $1.45, which is 88.2% below its 52-week high of $12.25, indicating a substantial decline. Additionally, the RSI is at 23.7, suggesting the stock is oversold, but this could reflect ongoing issues rather than a buying opportunity. The company reported a net loss of $30.23 million in Q2 2026, which is wider than the previous year's loss, and its forward P/E ratio is 0, indicating no expected earnings growth. The main risk is the recent downgrade by Morgan Stanley, which has reduced its price target to $1, reflecting low confidence in the company's future performance.

Valuation Metrics

The current forward P/E ratio for enGene Therapeutics Inc (ENGN) is 0.00, compared to its 5-year average forward P/E of -3.05.

Forward P/E

Overvalued

5Y Average P/E

-3.05

Current P/E

0.00

Overvalued

-0.13

Undervalued

-5.97

Forward EV/EBITDA

Fair

5Y Average EV/EBITDA

-2.08

Current EV/EBITDA

0.00

Overvalued

1.25

Undervalued

-5.40

Forward P/S

Overvalued

5Y Average P/S

4.30

Current P/S

20.60

Overvalued

12.61

Undervalued

-4.02

Alphio AI Price Scenarios for ENGN

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%ENGN

$4.68

Scenario price

B

Base

Base · 50%ENGN

$4.26

Scenario price

B

Bear

Bear · 25%ENGN

$3.67

Scenario price

Whales holding ENGN

N

Nextech Invest Ltd.

+ HoldingENGN

-1.90%

3M Return

ENGN FAQ — answered by Alphio AI

enGene Therapeutics Inc. is a clinical-stage biotechnology company mainstreaming non-viral genetic medicine through the delivery of therapeutics to mucosal tissues and other organs. The Company's lead program is detalimogene voraplasmid (also known as detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene at high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. Detalimogene is being developed using its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including Deoxyribonucleic acid (DNA) and various forms of Ribonucleic acid (RNA). It operates in the Healthcare sector.

enGene Holdings Inc is not a good buy right now due to significant financial losses and negative analyst sentiment. The current price is $1.45, which is 88.2% below its 52-week high of $12.25, indicating a substantial decline. Additionally, the RSI is at 23.7, suggesting the stock is oversold, but this could reflect ongoing issues rather than a buying opportunity. The company reported a net loss of $30.23 million in Q2 2026, which is wider than the previous year's loss, and its forward P/E ratio is 0, indicating no expected earnings growth. The main risk is the recent downgrade by Morgan Stanley, which has reduced its price target to $1, reflecting low confidence in the company's future performance.